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Background aims. Pancreatic cancer (pCa) is a tumor characterized by a ﬁbrotic state and associated with a poor prognosis.
The observation that mesenchymal stromal cells (MSCs) migrate toward inﬂammatory micro-environments and engraft into
tumor stroma after systemic administration suggested new therapeutic approaches with the use of engineered MSCs to
deliver and produce anti-cancer molecules directly within the tumor. Previously, we demonstrated that without any genetic
modiﬁcations, MSCs are able to deliver anti-cancer drugs. MSCs loaded with paclitaxel by exposure to high concentrations
release the drug both in vitro and in vivo, inhibiting tumor proliferation. On the basis of these observations, we evaluated the
ability of MSCs (from bone marrow and pancreas) to uptake and release gemcitabine (GCB), a drug widely used in pCa
treatment. Methods. MSCs were primed by 24-h exposure to 2000 ng/mL of GCB. The anti-tumor potential of primed
MSCs was then investigated by in vitro anti-proliferation assays with the use of CFPAC-1, a pancreatic tumor cell line
sensitive to GCB. The uptake/release ability was conﬁrmed by means of high-performance liquid chromatography analysis. A
cell-cycle study and secretome evaluation were also conducted to better understand the characteristics of primed MSCs.
Results. GCB-releasing MSCs inhibit the growth of a human pCa cell line in vitro. Conclusions. The use of MSCs as a “trojan
horse” can open the way to a new pCa therapeutic approach; GCB-loaded MSCs that integrate into the tumor mass could
deliver much higher concentrations of the drug in situ than can be achieved by intravenous injection.
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Recently, the approach to studying the biology of
cancer has been changed by the new concept of cancer
as an “anomalous organ” rather than simply a “tumor
mass” [1]. Indeed, this is a more complete and inte-
grated perspective because it considers the interaction
between cancer cells and the different tissue compo-
nents within the tumor mass (vascular system, stromal
and inﬂammatory cells, extracellular matrix [ECM])
that probably form a critical micro-environment forCorrespondence: Augusto Pessina, MD, Department of Biomedical, Surgical an
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different important roles, depending on the tumor
type, and the relationship among them may inﬂuence
cancer growth [3]. Fibroblasts, inﬂammatory cells (eg,
lymphocytes and macrophages), endothelial cells,
pericytes, smooth muscles and other cells may have
synergic effects on tumor progression. In this context,
for example, large differences may exist between the
normal and the tumor stroma and could play a deci-
sive role in tumorigenesis and development [4,5].d Dental Sciences, University of Milan, Via Pascal 36, 20133 Milan, Italy.
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adenocarcinoma (PDAC), the most common type of
pancreatic cancer and the fourth leading cause of
cancer death in the United States [6]. PDAC is very
aggressive and has a poor prognosis. Furthermore, its
resistance to chemotherapy and radiotherapy limits
the efﬁcacy of these therapeutic approaches.
Currently, PDAC is a deadly disease; the overall 5-
year survival rate is approximately 5% because of
the difﬁculty of early diagnosis, the highly aggressive
nature of the disease and the lack of effective thera-
pies [7]. After surgical curative resection (<20%),
only approximately 25% survive to 5 years because of
the high rate of local and metastatic recurrence [7,8].
Gemcitabine (GCB) and 5-ﬂuorouracil are the cur-
rent ﬁrst-line chemotherapies for locally advanced
and metastatic PDACs; however, these treatments
achieve a clinical response of only 10% [9e11];
hence, novel therapies are urgently needed.
It is well known that PDAC is characterized by the
proliferation of stromal ﬁbroblasts and deposition of
ECM, giving rise to a ﬁbrotic state known as des-
moplastic or reactive stroma. PDAC is associated
with poor prognosis [1] because of the propensity of
early metastasis and high resistance to both chemo-
therapy and radio-therapy [12]. Furthermore, des-
moplastic stroma contains small endothelium-lined
vessels and inﬂammatory cells that are not residual
atrophic components of parenchyma of the invaded
organ [13]. Several components might contribute to
the ﬁbroblast population: stellate cells, peri-vascular
ﬁbroblasts and bone marrow (BM)-derived cells; all
of them are activated by a tissue injury and accu-
mulate in the pancreas during carcinogenesis [14,15].
In the recent years, the ability of MSCs to migrate
toward inﬂammatory micro-environments and
engraft into tumor sites after systemic administration
[16] have led to the development of new therapeutic
approaches that are based on the cell-based delivery
of anti-cancer agents by MSCs, either gene-modiﬁed
or not gene-modiﬁed. Some authors [17,18] engi-
neered MSCs from different sources, such as the
adipose tissue and pancreas, respectively, to arm
them with tumor necrosis factor (TNF)-related
apoptosis-inducing ligand (TRAIL), an anti-cancer
death molecule able to induce apoptosis in several
tumor types. Recently, we have demonstrated that
MSCs are able to deliver anti-cancer agents without
any genetic modiﬁcations [19e21]. Indeed, when
exposed to high doses of the chemotherapeutic drug
paclitaxel, MSCs accumulated drug intracellularly
and then released it, reducing tumor proliferation
both in vitro and in vivo. To expand this line of study,
in the present study we evaluated the ability of BM-
or pancreas-derived MSCs to uptake GCB, the ﬁrst-
line chemotherapeutic drug for pCa treatment [22].We found that once loaded with GCB, MSCs were
able to release it into the culture medium, becoming
GCB-releasing-MSCs (MSCsGCB) that inhibited the
in vitro growth of a human adenocarcinoma cell line.Methods
Bone marrow MSCs
BM-MSCs were prepared from the mononuclear cell
fraction of human BM, which was purchased frozen
in liquid nitrogen from Lonza and stored at e120C
until use. After thawing, cells were suspended in
Dulbecco’s modiﬁed Eagle’s medium with low
glucose, 10% fetal bovine serum (FBS) (EuroClone),
2% L-glutamine and 10 ng/mL basic ﬁbroblast growth
factor (bFGF, ReliaTech), plated in 25-cm2 ﬂasks
(Corning) at 2  106 cells/mL and incubated at 37C,
5% CO2. After 48 h, ﬂoating cells were discarded;
medium was replaced and was then changed weekly
until cells reached 80% conﬂuency. The BM-MSC
monolayer was then trypsinized; cells were seeded at
the density of 5000 cells/cm2 and used until passage 3.Pancreas-derived MSCs
Primary human pancreatic tissues were obtained from
the digest remaining after the isolation of islet cells from
human pancreas, as previously described [23]. The
dense fraction recovered in the pellet and normally dis-
carded was processed for MSC isolation. After two
washes in phosphate-buffered saline (PBS), the equiva-
lent of a 1-mL packed pellet was re-suspended in a-
minimum essential medium (MEM) with 10% FBS,
plated in one T75 tissue cultureetreated ﬂask (Costar)
andgrownat37Cinahumidiﬁed incubatorat5%CO2.
After 24 h, the non-adherent material was removed and
fresh medium was added to the cells. Medium was
changed every 3 days. Cells were expanded in a-MEM
with 10% FBS, 1% L-glutamine and 10 ng/mL bFGF,
and, when 80% conﬂuency was reached, were trypsi-
nized and seeded at the density of 8000 cells/cm2. In
all the experiments, MSCs were used until passage 10.GCB priming of MSCs
GCB hydrochloride was purchased from Accord
Healthcare Limited. After reconstitution in 0.9%
sodium chloride injection, the stock solution (38 mg/
mL) was stored at e20C. On the day of experi-
ments, GCB was thawed and diluted in culture
medium to the required concentration.
Sub-conﬂuent MSC cultures (3e4  105 cells)
were exposed to 2000 ng/mL of GCB. Twenty-four
hours later, the cells were washed with PBS, trypsi-
nized, washed twice, and, after the evaluation of their
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concentration of 105 cells/mL. Forty-eight hours later,
the cell-conditioned media (CM) from primed MSCs
(MSCsGCB-CM) were collected, centrifuged at
2500g for 15 min to discard cell debris, aliquoted and
stored at e70C.
The remaining cells were trypsinized and
then lysed (MSCsGCB-LYS, see Supplementary
Information). Both CM and LYS were tested for
their in vitro anti-proliferative activity against
CFPAC-1, a human PDAC cell line sensitive to
GCB [24,25]. CM and LYS from untreated MSCs
were used as negative controls. CM from primed as
well as control MSCs were analyzed for their cytokine/
chemokine content by use of multiplex beadebased
assays on xMAP technology (Bio-Plex Human Cyto-
kine 27-Plex Panel; Bio-Plex Human Group II
Cytokine 21-Plex Panel; Biorad Laboratories).
Cell cycle and population doubling time (PDT)
were evaluated to compare untreated cells and 24-h
GCB-primed cells. Brieﬂy, cells were suspended in
PBS and ﬁxed with 96% (vol/vol) ethanol for 1 h at
4C. After PBS wash, cells were suspended in pro-
pidium iodide 50 mg/mL in PBS, incubated overnight
at 4C and analyzed by means of ﬂow cytometry
(FacsVantageSE, Becton-Dickinson). For the eval-
uation of PDT, see Supplementary Information.In vitro anti-proliferative assay on CFPAC-1 of GCB,
CM and LYS from MSCsGCB
The effects of GCB, MSCsGCB-CM andMSCsGCB-
LYS were studied on CFPAC-1 in 96-multi-well plates
(Greiner Bio-One) with the use of the 3-(4,5-dimethyl-
2-thiazolyl)-2,5-diphenyl-2-H-tetrazolium (MTT) assay
as previously described [19]. The inhibitory concen-
trations (IC50 and IC90) were determined according to
the Reed and Muench formula [26]. The anti-tumoral
activities of MSCsGCB-CM and MSCsGCB-LYS
were compared with pure GCB and expressed as
gemcitabine equivalent concentration (G.E.C.) ac-
cording to the following algorithm: G.E.C. (ng/mL) ¼
100/V50*IC50GCB. V50 is the volume (mL/well) of
MSCsGCB-CM or -LYS able to inhibit the prolifera-
tion of CFPAC-1 by 50%; IC50GCB is the concen-
tration (ng/mL) of pure GCB producing 50% of
inhibition. G.E.C., referred to a single primed MSC,
was calculated as the ratio between the total amount of
equivalent GCB and the number of cells seeded:
G.E.C. (pg/cell) ¼ G.E.C. (ng/mL)  CM or LYS
volume (mL)  1000/number of cell seeded.Direct in vitro inhibition of CFPAC-1 by MSCsGCB
To verify the ability of MSCs to inhibit the
in vitro CFPAC-1 proliferation, a co-cultureassay was performed by mixing 1000 tumor
cells (TCs) with eight different amounts of
MSCs (4000e2000e1000e500e250e125e63) to
achieve a ﬁnal proportion MSCs/CFPAC-1 of
4:1e2:1e1:1e1:2e1:4e1:8e1:16. This assay, con-
ducted in duplicate in 96-multi-well plates, was
performed on three experimental conditions: (i)
mixing CFPAC-1 and untreated MSCs; (ii) mixing
CFPAC-1 with MSCs primed with GCB
(MSCsGCB); (iii) CFPAC-1 (1000 cells/well only)
and MSCs alone (both normal and primed) at the
eight different amounts. The cultures were incubated
for 7 days in 95% air þ 5% CO2 at 37C; cell growth
was then evaluated by use of the MTT assay. The
results were expressed as a percentage of the prolif-
eration observed in TCs culture that did not receive
MSCs (considered as 100%). The arbitrary value of
R50 was calculated as the ratio of CFPAC-1/MSCs
able to inhibit TC proliferation by 50%.Evaluation of anti-angiogenic properties of MSCsGCB
To assess the anti-angiogenic potential of MSCs and
MSCsGCB, initially we tested the effect of GCB and
CM (collected after 48 h of culture from control and
GCB-primed MSCs) on the proliferation of human
umbilical vein endothelial cells (HUVECs) (Lonza).
HUVECs were routinely maintained in an endothe-
lial cell growth medium bullet kit (EGM) plus 10%
fetal calf serum (Lonza). Endothelial cell prolifera-
tion assay was performed as follows. Brieﬂy,
HUVECs at passage 3 were harvested by use of
trypsin, then re-suspended in EGM þ 0.2% bovine
serum albumin and counted. To evaluate the growth
response to CM from control and GCB-primed
MSCs, 0.5 mL of HUVECs (104 cells) were seeded
into each well of a 24-multi-well plate coated with
collagen type I; after cell adhesion, medium was
aspirated and replaced with EGM complete medium
supplemented or nonsupplemented with different
dilution (ranging from 1:2 to 1:8) of MSCs-CM and
MSCsGCB-CM. Negative and positive controls
were HUVECs grown in the basal medium (EBM),
respectively, without and with addiction of supple-
ments. Furthermore, the activity of GCB (from 10 to
1000 ng/mL) on HUVEC proliferation was evaluated
both in the basal and supplemented medium. After
72 h, the wells were washed, ﬁxed and stained. The
cells were counted with a calibrated ocular eyepiece
in 10 different ﬁelds at 40 magniﬁcation.Statistical analysis
Data tested for normality have been analyzed by
means of different statistical assays. Differences be-
tween two means were evaluated according to the
Figure 1. GCB sensitivity of BM-MSCs and pMSCs. The cytotoxic and anti-proliferative effects of GCB were evaluated by means of
MTT assay by culturing MSCs for 24 h (A) or 7 days (B) in the presence of increasing logarithmic concentrations of drug. The effects are
expressed, respectively, as cell viability and cell proliferation (percentages of the optical density measured in cultures that did not receive
GCB, considered as 100%). The reported values (mean  standard deviation) refer to one experiment performed in quadruplicate
(cytotoxicity) and to at least two experiments performed in triplicate (anti-proliferation). (C) Cell-cycle phase distribution analysis of
MSCs exposed to 2000 ng/mL of GCB for 24 h (CTRL indicates control cells, non-primed MSCs). Each value is the mean of two
experiments.
4 A. Bonomi et al.Student’s t-test; an analysis of variance test was
applied for comparing three or more groups. Two-
tailed P values >0.05 were not considered signiﬁcant.Results
Ex vivo expansion of MSCs and their characterization
The ﬂow cytometry analysis and the differentiation
assays (osteogenesis, adipogenesis and chondro-
genesis) conﬁrmed the mesenchymal/stromal
phenotype of BM-MSCs and pancreas-derived
MSCs (pMSCs). Reverse-transcriptaseepolymerase
chain reaction analysis revealed the expression of the
sodium-dependent concentrative nucleoside trans-
porter 1 (hCNT-1, Supplementary Figure S1) both
in BM-MSCs and pMSCs.Cytotoxic and anti-proliferative activity of GCB to
MSCs
In the 24-h cytotoxicity assay (Figure 1A), both BM-
MSCs and pMSCs showed a very high resistance to
GCB; even at the highest GCB concentration tested
(100,000 ng/mL), we observed a 20% to 30%reduction of cell viability. On the basis of these data
and the previous procedure developed with paclitaxel
[19], we selected to prime MSCs with 2000 ng/mL
for 24 h. These conditions were considered suitable
for GCB and both types of MSCs because (as
conﬁrmed by the cell-cycle analysis and the PDT
calculation) cell proliferation was almost completely
blocked but cell viability was not substantially
affected. Indeed, if primed cells were sub-cultured
for 144 h after MSCsGCB-CM collection, the
viability values were 75.55%  8.11% for BM-
MSCsGCB and 91.20%  4.53% for pMSCsGCB
(Supplementary Figure S2).
The cell-cycle analysis showed that high GCB
concentrations were able to produce a total arrest of
cell-cycle progression in all phases and not, as ex-
pected, a cell-cycle arrest in S phase only. Indeed,
after incubating both BM-MSCs and pMSCs for 24
h in 2000 ng/mL GCB, the percentages of cells in
G1, S and G2/M were not signiﬁcantly modiﬁed in
comparison to control samples.
The sensitivity of MSCs to the anti-proliferative
effect of GCB was assessed in a 7-day anti-
proliferation assay (Figure 1B). BM-MSCs and
pMSCs showed similar sensitivity, with IC50 values,
Figure 2. Anti-proliferative activity of MSCsGCB-CM on CFPAC-1. (A) Inhibitory activity of BM-MSCsGCB-CM and pMSCsGCB-CM
evaluated in CFPAC-1 standard assay in comparison to the standard drug. Tables on the right show V50 values, expressing the CM volume
(mL/well) able to produce a 50% inhibition of CFPAC-1 proliferation: this parameter, together with the IC50 value (ng/mL) assessed with the
pure drug, allows estimation of the GCB concentration in MSCsGCB-CM (G.E.C) and the amount of the drug released by a single primed
MSC, expressed as picograms (pg)/cell (see text for detailed equation). Results are expressed as percentages of the optical density measured
in CFPAC-1 grown in culture medium (for standard GCB curve) or CFPAC-1 grown in MSCs-CM (conditioned media collected from
non-primed MSCs, for MSCsGCB-CM). As shown by (B), CM collected from non-primed MSCs were ineffective on CFPAC-1 prolif-
eration. Values are expressed as mean  standard deviation of at least three independent experiments.
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Surprisingly, 10 ng/mL of GCB reduced cell prolif-
eration by 70% to 80%, but higher concentrations
did not increase the anti-proliferative effect.Evaluation of drug release from MSCsGCB on
pancreatic carcinoma cells
The activity of GCB released by MSCs was tested on
CFPAC-1, a human PDAC cell line very sensitive to
GCB (IC50 ¼ 0.71  0.26 ng/mL) (table in
Figure 2). MSCsGCB-CM produced a strong,
concentration-dependent anti-proliferative effect on
CFPAC-1, equivalent to that obtained with pure
GCB tested from 0.098 to 3.13 ng/mL (Figure 2A).
As demonstrated by the V50 values reported in the
box of Figure 2 (7.14  3.80 for BM-MSCs versus
11.68  7.48 for pMSCs), no signiﬁcant difference
in efﬁcacy was observed between CM from BM-
MSCsGCB and pMSCsGCB. The CM from con-
trol MSCs (non-primed with GCB) were ineffective
at inhibiting CFPAC-1 proliferation (Figure 2B).
By comparing the activity of 2-fold serial di-
lutions of MSCsGCB-CM with the inhibitory activ-
ity of pure GCB on CFPAC-1, we calculated an
equivalent GCB concentration (G.E.C.), and, withthe use of the value with the number of primed cells,
it was possible to estimate the amount of drug
released by a single primed MSC (expressed as pg/
cell). The values reported in the box of Figure 2
conﬁrm that MSCs derived from BM and pancreas
have the same ability to uptake and release amounts
of GCB that are effective against TCs.In vitro direct anti-proliferative activity of MSCsGCB
on CFPAC-1
The capacity of drug-loaded cells (MSCsGCB) to
inhibit TC proliferation by direct action was
conﬁrmed by use of a co-culture assay (MSCsGCB
and CFPAC-1 mixed at different ratios). As ex-
pected, the MSCsGCB inhibited the proliferation of
CFPAC-1 according to their proportional presence
(Figure 3A and Supplementary Figure S5a). An R50
value was calculated to represent the ratio (CFPAC-
1/MSCsGCB) able to reduce pancreatic carcinoma
proliferation by 50%. For BM-MSCs, R50 was 3.82
 2.31 and for pMSCs, 3.1  0.42, whereas MSCs
without loaded drug inhibited CFPAC-1 prolifera-
tion, with 50% inhibition occurring only at very high
ratios of BM-MSCs (R50 ¼ 0.25 ¼ 1/4). The direct
inhibitory potential of MSCsGCB in co-culture is
Figure 3. In vitro direct anti-proliferative activity of BM-MSCsGCB on CFPAC-1. The ability of BM-MSCsGCB to directly inhibit the
proliferation of CFPAC-1 was evaluated by use of a co-culture assay in a 96-well plate: 1000 tumor cells were mixed with different amounts
of BM-MSCs, both control and GCB-primed, to have seven different ratios BM-MSCs:CFPAC-1 (A). After a 7-day incubation, the
proliferation of CFPAC-1 was evaluated by use of MTT assay and expressed as percentage of the optical density (O.D.) measured for
CFPAC-1 cultured without BM-MSCs (A) or O.D. measured for CFPAC-1 cultured with non-primed BM-MSCs (-). Values are
expressed as mean  standard deviation of at least two independent experiments performed in duplicate. (B, C, D) CFPAC-1, BM-
MSCsþCFPAC-1 (1:1) and BM-MSCsGCBþCFPAC-1 (1:1) cultures, respectively.
6 A. Bonomi et al.shown in Figure 3 and Supplementary Figure S5, in
which the arrows indicate groups of CFPAC-1 cells
damaged by the GCB released by the co-cultured
loaded MSCs.Effect of MSCsGCB-CM on endothelial cell proliferation
As reported in Figure 4A, GCB was able to inhibit
HUVEC proliferation at three concentrations of
1000, 100 and 10 ng/mL. This inhibitory effect was
particularly evident when HUVECs were cultured in
EGM medium. In the absence of supplements
(EBM þ 10% FBS, the control medium), endothe-
lial cells had a very low growth rate and the inhibitory
activity of GCB was not signiﬁcant (compared with
cells grown without drug). CM derived from GCB-
primed BM-MSCs (Figure 4B) and pMSCs
(Figure 4C) caused signiﬁcant inhibition of HUVEC
proliferation in a concentration-dependent manner,
whereas CM from control MSCs did not inhibit
HUVEC proliferation.Discussion
Our data demonstrated for the ﬁrst time that MSCs
derived both from BM and pancreas can be loadedin vitro with GCB. Previously, we demonstrated the
ability of MSCs from different sources [19e21] to
accumulate and release PTX, a drug having a
mechanism of action compatible with many physio-
logical functions of the MSCs. Indeed, PTX binds to
a speciﬁc target in the MSC cytoskeleton, producing
a block of cell proliferation without affecting viability
or drug delivery. This new study on GCB uptake/
release by MSCs is very important because of the
wide use of this drug in treatment regimens for
pancreatic carcinoma [22].
A GCB loading concentration of 100,000 ng/mL
was only modestly cytotoxic (20% to 30%) to MSCs
derived from either BM or pancreas. This agrees with
the report by Schmidmaier [27] that GCB did not
affect BM-MSC viability up to 330 ng/mL. As ex-
pected, lower GCB concentrations (2.13  1.81 ng/
mL for BM-MSCs and 2.35  1.11 ng/mL for
pMSCs) blocked cell proliferation by 50%. GCB
concentrations higher than 10 ng/mL do not cause
any further changes in MSC proliferation, probably
because of the block in cell division (as conﬁrmed by
cell-cycle analysis and PDT calculation) despite the
high number of viable cells (MTT assay). The results
obtained by means of cell-cycle analysis agree with
the observation that low concentrations of GCB
induce cell-cycle arrest in the S phase, whereas high
Figure 4. Effect of BM-MSCs and pMSCsGCB-CM on endothelial cell proliferation (A) Inhibitory activity of GCB toward the human
endothelial cell line HUVEC. The inhibitory effect was particularly evident when HUVECs were cultured in EGM medium (basal
medium þ growth supplements). **P < 0.01 versus control (CTRL) in basal medium; P < 0.05 and P < 0.01 versus control in EGM
medium. (B, C) Inhibitory activity of conditioned media from, respectively, BM-MSCsGCB and pMSCsGCB toward HUVECs; both of
them were able to signiﬁcantly inhibit endothelial cell proliferation in a dose-dependent manner. *P < 0.05 and **P < 0.01 versus CTRL
(HUVECs grown in EGM medium). Bars in ﬁgures are means  standard deviations of three independent experiments.
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phases [28]. This situation represents the optimal
condition for loading the MSCs with drug; GCB at a
concentration of 2000 ng/mL blocks cell division but
maintains viability and drug accumulation.
GCB is a pro-drug (a cytidine analogue), inter-
nalized by nucleoside transporters. Once internal-
ized, GCB is di- and tri-phosphorylated by
deoxycytidine kinase into active metabolites that,
respectively, inhibit ribonucleotide reductase,
blocking de novo DNA synthesis, and incorporate
into DNA, making it more difﬁcult to repair [29,30].
No data are reported in the literature about the
expression of the concentrative nucleoside trans-
porter 1 (hCNT-1) and its role in MSCs. In our
model, we found that both BM-MSCs and pMSCs
expressed signiﬁcant levels of hCNT1, suggesting
that this transporter could play some roles in the
uptake of GCB by these cells.
MSCsGCB-CM were very active in inhibiting the
proliferation of the PDAC cell line, CFPAC-1,whereas the CM of untreated cells did not affect
tumor cell proliferation. High-performance liquid
chromatography (HPLC) analysis conﬁrmed the
presence of GCB in the CM and suggested that the
main inactivating mechanism of GCB (catalyzed by
deoxycytidine deaminase) is inactive in MSCs [30].
After 48 h of MSC subculture, the drug is not
completely released and some GCB remains inside
the cells, as demonstrated by the anti-tumor activity
of lysates from MSCsGCB and by HPLC analysis.
A single MSC can release 0.076 pg of GCB
(mean value between BM-MSCs and pMSCs). This
means that 106 MSCs, easily achievable, can deliver
76 ng of GCB and that GCB-primed cells injected
in vivo could release in situ (eg, in a typical tumor
volume of 1 mL) a drug concentration 100 times
higher than the IC50 value for CFPAC-1. A pre-
liminary study of co-culture MSCs/TCs performed
with the aim to set up follow-on preclinical studies in
mice conﬁrmed that the inhibitory effect of
MSCsGCB is directly proportional to their numbers.
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paracrine functions, and interest in their secretome
has increased during recent years because of its po-
tential application in regenerative medicine. Our
study was not intended to address this application of
MSCs; however, our preliminary investigation
showed that very high concentrations of GCB did not
modify the secretome of either BM-MSCs or pMSCs
treated with GCB, with the only exception being
interleukin (IL)12p40, which signiﬁcantly increased
(approximately 200-fold) in BM-MSCsGCB. We do
not know the mechanism behind the p40 stimulation
in BM-MSCs only. Because IL-12p40 is a subunit
shared with other members of the IL-12 family (eg,
IL-23), it is plausible that IL-12p40 and not IL-
12p70 could be upregulated. Because both IL12
and IL23 have a role in immune modulation and
inﬂammation, it will be interesting to investigate this
observation further and its possible role in BM-MSC
inﬂuence on the tumor micro-environment.
Indeed, the role of MSCs in pancreatic tumors is
a complex issue. These tumors are characterized by
important quantitative and qualitative effects of a
stroma constituted by both resident cells and those
that are attracted there from the BM by inﬂammatory
signals. BM-derived cells probably originate from a
CD45þ population resident in the BM that migrate
to the injured pancreas and give rise to pMSCs [15].
MSCs might support tumor growth by migrating
from the BM to blood vessels of pancreatic carci-
noma after the hypoxia-induced secretion of several
growth factors (GF): platelet-derived (PDGF),
epidermal (EGF) and vascular endothelial (VEGF).
Once located into tumor, MSCs interact with
endothelial cells and favor tumor blood vessel for-
mation through VEGF secretion [31]. MSCs derived
from BM appear to regulate epithelial to mesen-
chymal transition of a pancreatic tumoreinitiating
cell population and to maintain it [32]. In such a
complex picture, we suppose that a possible thera-
peutic strategy could lie in the use of the same MSCs
as a “trojan horse”: MSCsGCB could be integrated
into the tumor mass and deliver the drug in situ at
very high concentrations, difﬁcult to obtain by
intravenous injection. This could also contribute to
decrease severe toxic side effects.
Our in vitro study provides an important proof of
concept that needs conﬁrmation in vivo. As previ-
ously demonstrated with MSCs delivering PTX, we
think it is possible to develop a cytotherapy with the
use of MSCs co-loaded with GCB and PTX to
obtain the strongest anti-tumor effect in vivo. In fact,
as shown by preliminary experiments, MSCs can
uptake PTX and GCB in vitro during simultaneous
exposures (see Supplementary Information), and
their CM have an increased anti-tumor activity.Pre-clinical study is scheduled in our laboratory to
demonstrate the efﬁcacy of such a new therapeutic
approach that could open new perspectives for
treating such an aggressive neoplasia as pCa.Acknowledgments
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